Inicio › Cáncer de pulmón de células no pequeñas › Carolina del Norte

Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Carolina del Norte

79 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Carolina del Norte.

Ciudades en Carolina del Norte

Texto oficial del estudio (inglés)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Cone Health MedCenter Asheboro, Asheboro
Cone Health Cancer Center at Alamance Regional, Burlington
Wake Forest University at Clemmons, Clemmons
y 7 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Novant Health Weisiger Cancer Insititute ( Site 0266), Charlotte
Novant Health Forsyth Medical Center ( Site 0166), Winston-Salem

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06623422

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT07293247

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Duke University, Durham

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04585750

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Carolina Cancer Research Center, Wilson

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06270706

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #12, Durham

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT05176483

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Charles George VA Medical Center ( Site 3233), Asheville
UNC Lineberger Comprehensive Cancer Center ( Site 3250), Chapel Hill
WakeMed Raleigh Campus ( Site 3214), Raleigh

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07513376

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07388524

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

WakeMed Raleigh Campus ( Site 0144), Raleigh

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07554339

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Duke Cancer Center Cary, Cary
Durham VA Medical Center, Durham
Duke University Medical Center, Durham
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Novant Health Pharmacy Oncology Specialists, Winston-Salem

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07361497

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Novant Health Pharmacy Oncology Specialists, Winston-Salem

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07361510

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Carolinas Medical Center, Charlotte
Duke Cancer Center, Durham

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06765109

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06881784

A Study of PHN-012 in Patients With Advanced Solid Tumors

PHN-012-001 Site, Durham

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07127874

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

FirstHealth Cancer Center, Pinehurst
FirstHealth Moore Regional Hospital, Pinehurst
Carolina Cancer Research Center, Wilson

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07222566

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Messino Cancer Centers Asheville, Asheville
Duke University Medical Center, Durham
FirstHealth Cancer Center, Pinehurst

ReclutandoFase 3

Edades de 18 a 100 · Todos los sexos · Actualizado el 25 sept 2026 · NCT05920356

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Levine Cancer Institute, Charlotte
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT04253964

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Brody School of Medicine at East Carolina University, Greenville
ECU Health Medical Center, Greenville
Carolina Cancer Research Center, Wilson

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Atrium Health, Charlotte
Regional Medical Oncology Center, Wilson
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06667076

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

University of North Carolina at Chapel Hill, Chapel Hill
FirstHealth of the Carolinas, Pinehurst

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06667908

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

WakeMed Raleigh Campus, Raleigh

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06890598

Pan-tumor MRD Study

Carolina Oncology Specialists, Charlotte
Southeastern Medical Oncology Center (SMOC), Goldsboro
Regional Medical Oncology Center, Wilson

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT03191149

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

East Carolina University, Greenville

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT06561386

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Greenville
Research Site, Salisbury

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT06357533

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Fletcher Hospital, Inc. dba AdventHealth Hendersonville, Hendersonville

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06712316

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

FirstHealth of the Carolinas- Speciality Center /ID# 272924, Pinehurst

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06568939

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Atrium Health Levine Cancer, Charlotte
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT05696782

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Duke Cancer Center Durham, Durham

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07488676

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0624, Asheville

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06875310

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

FirstHealth of the Carolinas, Inc., Pinehurst

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT06745882

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Wilson

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Chapel Hill
Clinical Study Site, Durham
Clinical Study Site, Pinehurst

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06767514

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Carolina Biooncology Institute, Huntersville

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT05267626

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Levine Cancer Institute, Charlotte
Durham VA Health Care System, Durham

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07195695

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Duke University School of Medicine, Durham

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Duke University Medical Center, Durham

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT04613596

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

FirstHealth Cancer Center, Pinehurst
Carolina Cancer Research Center, Wilson

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT06899126

Effects of Infusion Timing on Treatment Response in Solid Tumors

University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT07630168

De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.